



Autism Innovative Medicine Studies-2-Trials

Start date:	1-6-2018
Runtime:	60 months
End date:	31-5-2023
EC Funding:	EC Horizon 2020
Coordinator:	KING'S COLLEGE LONDON (KCL)

#### General information:

The research programme includes a range of studies carried out by different groups. These will explore how autism develops, from before birth to adulthood, and how this varies in different people. We will look for [biological markers](#) which indicate whether a person has or may develop particular characteristics. These markers could help to identify who may ultimately benefit from particular treatments. We will also [test medicines](#) to help with social difficulties, repetitive behaviours and sensory processing. To accelerate medicine development, we will build a [network](#) of connected people across Europe and beyond. AIMS-2-TRIALS will put Europe at the forefront of autism research.

#### Vision and impact:

Our objectives:

- Understand how autism, and its co-occurring health conditions, develop from before birth into adulthood.
- Identify features of autism that can be measured, called biomarkers
- Test new medicines that could become a treatment option for autistic people
- Build a network to connect researchers, clinicians and the autism community
- Prepare Europe to pioneer large clinical trials of future medicines
- Improve and accelerate the process of developing new medicines
- Analyse and manage the data collected in research
- Explore how policies on autism can better support autistic people
- Develop educational tools to improve understanding of autism
- Put Europe at the forefront of autism research

#### Project Website:

[www.aims-2-trials.eu](http://www.aims-2-trials.eu)



[Project] has received funding from the European Union's Horizon 2020 Research and Innovation Programme under Grant Agreement n° 777394